Brown, Lisle/Cummings, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $376 Billion
- Q2 2025
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 132 shares of ALNY stock, worth $56,750. This represents 0.01% of its overall portfolio holdings.
Number of Shares
132
Previous 132
-0.0%
Holding current value
$56,750
Previous $35.6 Million
20.76%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
748Shares Held
114MCall Options Held
851KPut Options Held
817K-
Capital World Investors Los Angeles, CA16.8MShares$7.22 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.72 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.1 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.09 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.9 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...